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Glucuronidation enzymes, genes and
psychiatry
Jose de Leon
University of Kentucky (UK) Mental Health Research Center at Eastern State Hospital, Department of Psychiatry,
UK College of Medicine, Lexington, KY, USA
Abstract
The phase I cytochrome P450 (CYP) isoenzymes have received substantial attention in the pharmaco-
genetic literature. Researchers are beginning to examine the role of the phase II UDP-glucuronosyltrans-
ferase (UGT) enzymes, which produce products that are more water-soluble, less toxic and more readily
excreted than the parent compounds. Several reasonsmay have contributed to neglect of UGTs (compared
to CYPs) including: (1) the overlapping activity of UGTs and lack of selective probes; (2) the complexity of
the glucuronidation cycle; and (3) the difficulty in developing analytic methods to measure glucuronides.
Current CYP knowledge is used as a model to predict advances in UGT knowledge. At least 24 different
UGT human genes have been identified and are classified in two families (UGT1 and UGT2) based on
sequence homology. The UGT1A subfamily (genes located on chromosome 2) glucuronidates bilirubin,
thyroid hormones, and some medications. UGT1A4 metabolizes tricyclic antidepressants and some anti-
psychotics. The UGT2B subfamily (genes located on chromosome 6) glucuronidates sexual steroids and
bile acids. Oxazepam and lorazepam are mainly metabolized by glucuronidation. Anti-epileptics with
mood-stabilizing properties are frequently metabolized by UGTs. Opioid and nicotine addiction may also
be influenced by glucuronidation. Glucuronidation of serotonin may be important during fetal develop-
ment. UGTs appear to be in small concentrations in brain tissue (and higher concentrations at brain
capillaries). However, UGTs may be localized in certain brain areas to provide a neuroprotective function.
This review illustrates the importance of glucuronidation and the implications for psychiatry.
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Introduction
The Human Genome Project is providing a myriad of
new genes influencing brain function. The function of
these genes will need to be determined once the se-
quence is known. Current knowledge of genes influ-
encing brain function is limited, and most mental
illness appears to be complex and influenced by many
genes and possibly numerous environmental factors.
The study of genes, which control the systems as-
sociated with psychopharmacological treatments, ap-
pears to be a good starting point. One can focus on
genes controlling neurotransmission (pharmacody-
namics) or on genes involved in controlling pharma-
cokinetic factors (absorption, distribution, metabolism
and elimination of drugs). The pharmacogenetic
literature has focused on genes that mediate pharma-
cokinetics (Alvan et al., 2001; Kirchheiner et al., 2001)
and more recently, genes influencing pharmacody-
namics have been investigated. However, the psychi-
atric literature, particularly in schizophrenia (Cichon
et al., 2000; Kawanishi et al., 2000; Malhotra, 2001;
Rietschel et al., 1999) has mainly focused on genes that
mediate pharmacodynamics while neglecting those
that influence pharmacokinetics.
It is very probable that variations in genes affecting
drug handling make substantial contributions to the
wide interpatient variability in response to drug ther-
apy often seen in psychiatric patients or to drug
addictions. Advances in pharmacogenetics may not
be a magic answer for psychopharmacotherapy im-
provements. Psychiatric disorder complexities and
poor compliance of psychiatric patients contribute to
the difficulty of treating psychiatric patients. Some
cases of poor compliance may be explained by
adverse drug reactions associated with polymorphic
variations.
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The metabolic enzymes are traditionally divided
into two categories, phase I (oxidation, reduction, or
hydrolysis) and phase II (conjugation) enzymes (Bertz
and Granneman, 1997; Shen, 1997). Glucuronidation
enzymes are the most important group of the phase II
enzymes and are the focus of this review. UDP-
glucuronosyltransferase (UGT) enzymes produce
products that are more water-soluble, usually less
biologically active, and more readily excreted than the
parent compounds. The glucuronides can be excreted
by renal and biliary elimination. The glucuronides
eliminated by the biliar system can be reabsorbed
using the enterohepatic cycle.
The cytochrome P450 (CYP) isoenzymes are the
most important group of enzymes of phase I reactions
(Rendic and Di Carlo, 1997; Touw, 1997). Compared
to CYP, the UGTs have been neglected by researchers.
Several reasons may have contributed to this neglect,
including: (1) the UGT system includes many en-
zymes whose activity overlaps, and in contrast with
CYPs, there are few selective probes; (2) the com-
plexity of the glucuronidation cycle, that may include
in-vivo deconjugation by b-glucuronidase and re-
absorption in the enterohepatic cycle; and (3) glucu-
ronide analyses represents a serious challenge, since
more sophisticated methods such as liquid chromato-
graphy–mass spectrometry (LC–MS) or radiochemical
high-performance liquid chromatography (HPLC)
(Ethell et al., 1998) are needed, and frequently ana-
lytical standards are missing since pure conjugated
products are unavailable (Hawes, 1998). It is difficult
to synthesize glucuronidation products, particularly
N-glucuronides, and frequently there are no com-
mercial sources (Hawes, 1998). It is easier to establish
glucuronide concentrations by indirect analysis
(Hawes, 1998). First, the concentration of the parent
compound is established, then the parent compound
glucuronide is hydrolysed (by chemical or enzymic
hydrolysis) leading to an increase of the parent com-
pound. Therefore, the glucuronide concentration is
calculated by subtracting the concentration of the
parent compound before hydrolysis from the concen-
tration of the parent compound after hydrolysis.
Better knowledge of CYP and UGTs will surely ex-
plain some psychopharmacological treatment failures,
drug intoxications and adverse drug events. Knowl-
edge of a patient’s genome, including those genes of
metabolic enzymes, will greatly facilitate the selection
of individualized psychopharmacological treatments.
With the new advances in technology, this may be
highly plausible in the near future. The journal Science
(Editorial comment, 1997) stressed the importance of
this approach by naming ‘personalized prescriptions’
as one of the six research horizons for 1998. In 1999, the
lay journal Time predicted that by 2015, GeneChips
will be used to tailor medications to each patient’s
genes and prevent adverse drug reactions (Lertola,
1999). In effect, the development and marketing of
new technologies such as GeneChips (Flockhart and
Webb, 1998; Watson and Akil, 1999) will permit
simultaneous testing of multiple genes ensuring that
pharmacogenetical testing will be a cost-effective tool
for clinicians (Wedlund and de Leon, 2001). The con-
sequences of genetic polymorphism are more pro-
nounced when a given pharmacological substrate
has a narrow therapeutic range or when the genetic
defect causes a complete lack of enzyme activity (e.g.
CYP2D6). In fact in 2003, the CYP2D6 GeneChip
may be presented to the US Food and Drug Adminis-
tration (FDA) in order to get approval for marketing.
UGT genotyping with new techniques, such as the
GeneChip, may be very helpful but other issues (such
as enzymic overlap, influence of the enterohepatic
cycle, and lack of development of analytic methods
to measure glucuronides) may affect its practical use.
To date, the consequences of genetic polymorphism
for UGTs has been definitely established only for
bilirubin (de Wildt et al., 1999) and for a metabolite of
irinotecan, an anti-neoplasic drug (Iyer et al., 2002).
The example of CYP
A parallel exists between current knowledge of the
UGT gene family and the knowledge of the CYP gene
family 10 years ago. Since data on the significance of
glucuronidation is limited, one could examine the
CYP system as a model to illustrate potential clinical
implications. The CYPs are a superfamily of enzymes
(Touw, 1997). Many CYPs are essential for life since
they are involved in the formation and/or metabolism
of critical endogenous compounds (Rendic and Di
Carlo, 1997). The CYPs from the first three families
are located in the endoplasmic reticulum and appear
to be involved in the phase I metabolism of xenobiotic
compounds. Each species has its own CYP family.
The current theory suggests these enzymes evolved
to metabolize chemicals produced by plants. An
animal–plant warfare exists where the CYP enzymes
in each species have evolved to facilitate the elimin-
ation of toxicants most likely found in their foods.
Humans use the same CYPs to destroy medications
(many derived from plants) that have evolved over
many generations as protectants against plant toxi-
cants.
The CYP2D6 isozyme metabolizes many anti-
psychotic and antidepressant drugs. The gene that
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encodes this enzyme is located on chromosome 22.
The CYP2D6 enzyme is expressed constitutively in
several tissues so enzyme activity is defined primarily
by the type of CYP2D6 alleles expressed in a subject.
The only significant environmental factor that may
modify the phenotype is the intake of potent inhibitors
such as quinidine, paroxetine, or fluoxetine. Therefore,
it would seem reasonable for psychiatric researchers
and psychiatrists to examine variations in this gene to
assess how it may influence response to antipsychotic
and antidepressant medications. There is an increas-
ing number of studies on the association of CYP2D6
allelic variations with therapeutic or toxic effects after
psychopharmacological treatments for both anti-
psychotics (Armstrong et al., 1997; Arthur et al., 1995;
Iwahashi, 1994; Pollock et al., 1995) and antidepress-
ants (Bertilsson et al., 1981, 1985; Bork et al., 1999;
Chen et al., 1986; Krau et al., 1996/1997; Meyer et al.,
1998; Spina et al., 1997). Guidelines for antidepressant
dosing according to the CYP2D6 genotype have been
developed (Kirchheiner et al., 2001). One study has
shown that extremes (associated with a lack of activity
or abnormally high activity) of the CYP2D6 genotype
may be associated with a greater incidence of side-
effects (de Leon et al., 1998) and higher treatment costs
by extending the length of hospitalizations (Chou
et al., 2000). Other more recent pharmacogenetical
studies in psychiatry combined genotyping of other
CYPs and dopamine receptors (Ozdemir et al., 2001;
Segman et al., 2002).
A more interesting finding for most psychiatrists
and psychiatric researchers is the role of CYP2D6 on
brain function. CYP2D6 is found in some brain areas
and may play an important role in protecting certain
susceptible brain regions from toxicants that gain ac-
cess to the CNS. The enzyme appears to be distributed
close to areas rich in the dopamine transporter. Some
earlier studies suggested that the CYP2D6 genotype
may influence the development of Parkinson’s dis-
ease. For instance, poor CYP2D6 metabolizers (in-
dividuals who lack CYP2D6) may be more prone to
develop Parkinson’s disease (Tanner, 1991). A more
recent meta-analysis suggested that the median odds
ratio for poor CYP2D6 metabolizers in Parkinson’s
disease was 1.32 (95% confidence interval 0.98–1.78),
indicating that being a poor metabolizer may slightly
increase the risk of Parkinson’s disease, but this was of
borderline statistical significance (Rostami-Hodjegan
et al., 1998). The CYP2D6 genotype may also be as-
sociated with Lewy body dementia (Saitoh et al., 1995),
probably related to Parkinson’s disease. However, it
does not appear to be associated with Alzheimer’s
disease (Cervilla et al., 1999).
UGT
Ten years ago knowledge of the UGT enzymes in
psychiatry could be summarized as follows: the UGTs
are a group of liver enzymes that metabolize some
psychiatric medications. At that time the knowledge
on genetic disorders of UGTs was limited to two dis-
eases with patronymic names associated with hyper-
bilirubinaemia due to inherited deficiencies in the
UGTs (Crigler–Najjar syndrome and Gilbert’s syn-
drome). The Crigler–Najjar syndrome is a rare familial
form, frequently lethal, of severe unconjugated hyper-
bilirubinaemia caused by an absence of bilirubin
conjugation. Gilbert’s syndrome is a familial hyper-
bilirubinaemia characterized by a mild unconjugated
hyperbilirubinaemia that is estimated to be found
in 5% of the Caucasian population. The formation of
bilirubin diglucuronide is decreased and the level
of bilirubin monoglucuronide is increased (Burchell
et al., 2000).
Our current knowledge in this area is somewhat
more extensive. It has been suggested that UGTs may
influence carcinogenesis and autoimmunity (Tukey
and Strassburg, 2000). This review tries to suggest the
possibility that advances in this area may have some
significant implications for psychiatry and psychiatric
research. Moreover, the role of UGTs is not confined
to hepatic metabolism. The olfactory epithelia express
a specific UGT isoenzyme responsible for the glucu-
ronidation of odorants thereby facilitating the termin-
ation of receptor occupation and signal transduction
by olfactory stimulants (Burchell et al., 1998).
UGT is located in the endoplasmic reticulum of
hepatic and extra-hepatic tissue (particularly skin,
lung, small intestine and kidney) (Kroemer and Klotz,
1992). These enzymes transfer the glucuronyl group
from uridine-5k-diphosphoglucuronate (Figure 1) to
many compounds having nucleophilic functional
groups of oxygen, nitrogen, sulphur, or carbon. The
resulting glucuronide is more water-soluble, less toxic,
and more easily excreted than the parent compound.
Glucuronides account for most of the detoxified ma-
terial found in bile and urine. UGTs have evolved to
catalyse the glucuronidation of both endogenous
compounds (bilirubin, thyroid hormones, sexual hor-
mones and serotonin) and xenobiotics (e.g. aceta-
minophen and morphine are predominantly cleared
in this way). The biological importance of glucuro-
nidation is grossly under-investigated, although, it
seems reasonable to postulate that it serves primarily
to enhance the elimination of substrates from the body
(Clarke and Burchell, 1994). However, the glucu-
ronidates at the D-ring of oestriol, testosterone, and
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dihidroxytestosterone have biological activity and
may contribute to cholestasis in animal studies. In
contrast, A-ring glucuronidation of these steroids is
associated with inactivation. It is also possible that the
non-steroidal anti-inflammatory drugs (NSAIDs) and
other drugs containing carboxylic acid groups may be
converted by glucuronidation to more reactive prod-
ucts that bind to proteins and other cellular macro-
molecules (Mackenzie et al., 2000). In fact, zomepirac,
a NSAID removed from the US market due to high
risk of anaphylaxis, undergoes irreversible protein
binding after glucuronidation (Liston et al., 2001).
UGTs and their polymorphic variations
At least 24 different human UGT genes have been
identified (Burchell et al., 1995; Mackenzie et al., 1997,
2000; Tukey and Strassburg, 2000) and are classified in
two subfamilies based on sequence identity, namely
the UGT1 subfamily glucuronidates bilirubin and
xenobiotic phenols and the UGT2 subfamily glucu-
ronidates steroids and bile acids. Like the CYPs, each
species appears to have its own UGTs with different
substrates (Walton et al., 2001). Across species, anal-
ogous UGTs may have different levels of activity for
the same drug.
The UGT1 subfamily is derived from a single gene
locus at 2q37 with at least 13 unique varieties of exon 1
and four common exons 2–5 (de Wildt et al., 1999).
Each exon 1 is preceded by its own promoter region
and encodes a unique UGT isoform. The messenger
RNA encoding each UGT isoform is formed by fusion
of one type of exon 1 to the four exons 2–5. The iso-
enzymes share a conserved domain (3k or C half) and
have a variable domain (5k or N half). Gene mutations
in the common exon 2–5 region can lead to changes in
activity and/or expression of all isoforms, while gene
mutations in the unique exon 1 or promoter region
may only affect the unique isoform involved (de Wildt
et al., 1999). The UGT1A1, UGT1A3, UGT1A4 and
UGT1A9 are the best-known isoenzymes and are ex-
pressed in the liver. Other isoenzymes of this family
appear not to be expressed in the liver but rather
in gastrointestinal epitheliums (UGT1A7 in gastric
epithelium, UGT1A8 in colonic epithelium, and
UGT1A10 in gastric, colonic, and biliary epithelium)
(Strassburg et al., 1998). UGT1 liver expression ap-
pears to show little inter-individual variation, in con-
trast to important inter-individual variations in gastric
(Strassburg et al., 1998) and small intestinal epithelium
(Strassburg et al., 2000). It is probable that UGT1
polymorphisms, particularly those in the promoter
area, may have tissue-specific consequences and may
be more evident after oral administration. In particu-
lar, jejunal UGT activity may have important conse-
quences in drug metabolism variations (Strassburg
et al., 2000).
UGT1A1 displays affinity for a variety of com-
pounds besides bilirubin, including steroids and thy-
roid hormones (Table 1). More than 30 different
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Figure 1. Glucuronidation of nicotine and nicotine metabolites.
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mutations of the UGT1A1 gene have been associated
with the Crigler–Najjar syndrome. Type I is associated
with absence of enzyme activity while in type II,
UGT1A1 activity is much reduced (de Wildt et al.,
1999). In type I (an autosomal recessive disorder), the
most typical mutations have been found in exons 2–5,
encoding the constant regions of all UGT1 enzymes
(Burchell et al., 1998).
According to in-vitro and in-vivo studies, the ac-
tivity of UGT1A1 in Gilbert’s syndrome is reduced to
30% of normal levels (Burchell et al., 2000). Particu-
larly in Caucasians, the polymorphism that leads to
Gilbert’s syndrome consists of differences in TA re-
peats in the promoter region (Table 2). The normal
wild-type form includes six repeats, (TA)6TAA. More
TA repeats are associated with lower activity. The sev-
en-repeat (TA)7TAA sequence is found in Caucasian
populations while eight repeats (TA)8TAA is found
in African populations. In the latter, a five-repeat
variation associated with increased activity has been
described (Iyer, 1999; Iyer et al., 1999; Mackenzie et al.,
2000). Thus, in Caucasians, Gilbert’s syndrome ap-
pears to be strongly associated with homozygosity for
allele (TA)7TAA (designed genotype 7/7). Homo-
zygosity for allele 7 (7/7) is present in 11–13% of
Scottish, 17–19% of Canadian Inuits, up to 23% of
Africans and less than 3% of Japanese (Burchell et al.,
2000). Other mutations may affect UGT1A1 function.
Asian populations have a low (TA)7TAA allele fre-
quency (0.15) but two additional missense mutations
in the coding region (Table 2) have been found
(Burchell et al., 2000; Iyer, 1999; Lampe et al., 2000;
Mackenzie et al., 2000).
The toxicity to an anti-neoplasic drug, irinotecan,
may be influenced by the presence of Gilbert’s syn-
drome (Iyer et al., 1999). Specifically, UGT1A1 plays
a role in the detoxification of the active metabolite
SN-38. In a recent prospective study of 20 patients
Table 1. Possible UGT substrates and inducers
Isoenzyme
Substrates
Possible inducersEndogenous Medications Probes
UGT1A1 Bilirubin SN-38 Emodin Phenobarbital
Catechol oestrogens Ethenyl oestradiol Bilirubin
T4 and rT3 Buprenorphine
Naltrexone
UGT1A3 Catechol oestrogens Cyproheptadine
Clozapine
Amitriptyline
UGT1A4 Pregananediol Many antipsychotics Imipramine Carbamazepine
Many TCAs Phenytoin
Cyproheptadine
Promethazine
UGT1A6 Serotonin Acetaminophen Acetaminophen Smoking
1-Naphthol Cruciferous vegetables
UGT1A9 T4 and rT3 Acetaminophen Propofol Smoking
Oestrogens Cruciferous vegetables
UGT2B4 Bile acids Hyodeoxycholic acid
UGT2B7 Bile acids Clofibrate Morphine Cruciferous vegetables
Androsterone Propanolol
Several androgensa NSAID
Oestrogens Epirubicin
Catechol oestrogens Many opioids
Serotonin Zidovudine (AZT)
UGT2B15 Several androgensa
UGT2B17 Several androgensa
Androsterone
a Several androgens: androstenodiol, testosterone and dihidrotestosterone.
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with solid tumours, Iyer et al. (2002) found that
patients with the (TA)7TAA polymorphism had sig-
nificantly lower SN-38 glucuronidation rates and more
adverse drug reactions. Patients homozygous for allele
(TA)7TAA (genotype 7/7) and heterozygous with
one allele (TA)7TAA, and one allele (TA)6TAA (geno-
type 6/7) have respectively 50 and 25% decreases in
glucuronidation of SN-38 when compared to patients
homozygous for allele (TA)6TAA (genotype 6/6) (Iyer,
1999). Two other recent pharmacokinetic studies with
patients taking irinotecan also supported the view that
this polymorphic variation influences SN-38 glucuro-
nidation (Ando et al., 2002; Xie et al., 2002).
Myaoka et al. (2000a,b) have suggested that schizo-
phrenia is associated with Gilbert’s syndrome in
Japan, unfortunately, they did not verify the presence
of Gilbert’s syndrome with genetic testing and only
used the hyperbilirubinaemia to make the diagnosis.
It is not possible to rule out that other environmental
factors including medications or medications remain-
ing in the body after their discontinuation may ex-
plain the differences in hyperbilirubinaemia between
schizophrenic patients and other patients.
UGT1A3 (Table 1) catalyses glucuronidation of
primary, secondary, and tertiary amines, coumarins,
flavinoids, and oestrones (Green et al., 1998; Liston
et al., 2001). It shares more than 90% of its amino-acid
sequence with UGT1A4, but it has low efficiency
compared to UGT1A4 (Green et al., 1998; Liston
et al., 2001).
UGT1A4 (Table 1) catalyses N-glucuronidation of
tertiary amines and other xenobiotics (Burchell and
Coughtrie, 1997). The UGT1A4 isoform may be the
most important isozyme for the glucuronidation of
some tricyclic antidepressants (TCAs) and some typi-
cal and atypical antipsychotics (Green et al., 1998;
Green and Tephly, 1998). Imipramine may be a probe
for UGT1A4 (Burchell and Coughtrie, 1997).
UGT1A6 (Table 1) metabolizes planar phenolic
compounds (Burchell et al., 2000). Two missense mu-
tations have been identified (Table 2). The presence of
both mutations in a single allele was detected in up to
30% of the population with some ethnic variations
(Lampe et al., 2000). In-vitro studies using cultured
cells with both mutations suggest that they may affect
function but it is unclear whether this decrease in
function has any in-vivo implications (Mackenzie et al.,
2000).
UGT1A9 is more promiscuous than UGT1A6 as
it metabolizes many bulky phenols. The substrates
include drugs such as acetaminophen, and some
endogenous compounds (Table 1).
Table 2. UGT polymorphic variations
UGT genes Polymorphisms Functional effects
UGT1A1 Several in coding region Crigler–Najjar syndrome (very rare) when patient has mutations in
both chromosomes
(TA)7 TAA in promoter Decreased activity (most Gilbert’s syndrome cases in Caucasians have
homozygous alleles)
(TA)8 TAA in promoter Decreased activity (African–Americans)
(TA)5 TAA in promoter Increased activity (African–Americans)
G71Ra in coding region Decreased activity (Asians)
Y486Db in coding region Decreased activity (Asians)
UGT1A6 T181Ac in coding region Both mutations combined cause lower activity in vitro;
probably no clinical significance
R184Sd in coding region
UGT2B4 D485Ee in coding region It is not clear that is associated with changes in functional activity
F109L+F396Lf in coding
region
Rare. Lower activity in vitro but probably with no clinical significance
UGT2B7 Y268Hg in coding region Probably no functional effects in spite of earlier suggestion of being
functional
UGT2B15 D85Yh in coding region No functional effects
a Change from glycine (G) to arginine (R) at position 71; b change from tyrosine (Y) to aspartate (D) at position 486; c change
from threonine (T) to alanine (A) at position 181; d change from arginine (R) to serine (S) at position 184; e change from aspartate
(D) to glutamate (E) at position 485; f change from phenylalanine (F) to leucine (L) at positions 109 and 396; g change from
histidine (H) to tyrosine (Y) at position 268; h change from aspartate (D) to tyrosine (Y) at position 85.
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The UGT2 family has subfamilies. The olfactory-
specific isoforms are included in the UGT2A sub-
family. In humans, UGT2A1 is expressed in olfactory
epithelium, brain, and fetal lung (Tukey and Strass-
burg, 2000). The UGT2B subfamily includes metabolic
enzymes that are responsible for the glucuronidation
of steroids and bile acids. The UGT2Bs are synthesized
from a series of at least five similar genes located in
a cassette on the chromosome 4q13 (Burchell et al.,
2000). The UGT2B4 gene has been isolated and has five
introns and six exons (17.5 kb). The UGT2B7 is also
located on chromosome 4. UGT2B15 and UGT2B17
metabolize androgens and are also mapped there.
UGT2B4 metabolizes steroids and bile acids
(Table 1). Two polymorphisms with ethnic variations
have been identified (Table 2) but it is unclear whether
they affect function (Lampe et al., 2000; Mackenzie
et al., 2000).
UGT2B7 (Table 1) metabolizes steroids, bile acids
and many opioids (Burchell et al., 1995; Burchell and
Coughtrie, 1997; Liston et al., 2001). A polymorphic
variation, H268Y (Table 2), has been described with
different frequencies in Caucasians and Japanese sub-
jects (Lampe et al., 2000). Patel et al. (1995a) showed
that ketoprofen, as well as other substrates of UGT2B7,
competitively inhibit the (S)-oxazepam glucuronida-
tion. Following that, Patel et al. (1995b) suggested
that 10% of Caucasians are poor glucuronidators of
S-oxazepam. They proposed that the UGT2B7–H268Y
polymorphism may account for this difference in S-
oxazepam metabolism. In an in-vitro study, Coffman
et al. (1998) found that oxazepam is a poor substrate
for UGT2B7. Several recent studies suggest that H268Y
polymorphic variation does not influence metabolism
of UGT2B7 substrates, including morphine (Bhasker
et al., 2000; Coffman et al., 1998; Holthe et al., 2002;
Innocenti et al., 2001).
UGT2B15 metabolizes a wide range of phenols in-
cluding steroids, and food-derived flavones and fla-
vinoids. Two polymorphic variations (Table 2) with
ethnic variations have been described. Each allele
accounts for approximately half of the alleles in Cau-
casians. As both alleles have similar substrate speci-
ficities and kinetic characteristics, it extremely unlikely
that this polymorphism has clinical significance
(Mackenzie et al., 2000).
Other factors may influence UGT function besides
polymorphic gene variations
Hepaticglucuronidationundergoessignificantchanges
during fetal and neonatal development. Therefore,
age-adapted drug therapy may be required. UGTs
do not appear to be detected in fetal liver until 20 wk
gestation. After 6 months of life UGTs are present,
but UGT1A9 and UGT2B7 appear to show remarkable
lower expression even beyond 2 years (Leakey et al.,
1987; Strassburg et al., 2002).
Several drugs metabolized by glucuronidation
appear to inhibit UGTs in a non-specific way. Lor-
azepam, oxazepam, TCAs, valproic acid, ketoprofen,
and probenecid appear to inhibit several UGTs. No
specific UGT inhibitors have been identified but are
now being investigated (Golovinsky et al., 1998).
In-vitro studies (Bock et al., 1999; Munzel et al.,
1999) suggest that the polycyclic aromatic hydro-
carbons found in tobacco smoke appear to cause en-
zymic induction at UGT1A6 and UGT1A9 by binding
to an intracellular aryl hydrocarbon receptor (Fuhr,
2000). According to these studies, some food anti-
oxidants, such as those found in cruciferous vegetables
(e.g. broccoli) appear to induce UGT1A6, UGT1A9 and
UGT2B7 (Munzel et al., 1999). Phenobarbital is an
inducer of UGT1A1 (Bock et al., 1999) and has been
used to treat neonatal hyperbilirubinaemia. Carb-
amazepine and phenyotoin appear to be UGT1A4
inducers, since they are inducers of lamotrigine, a
UGT1A4 drug not metabolized by CYP1A2.
According to studies in rats, some hormones, e.g.
thyroid hormones and growth hormone, may influ-
ence the activity of UGTs. In humans, it has been
shown that hypothyroidism may decrease the glucu-
ronidation of oxazepam (Sonne, 1993). Little attention
has been paid to the effects of sexual hormones on
UGTs (Gueraud and Paris, 1998). It is believed that
androgens may influence its own metabolism by in-
fluencing UGT activity in different tissues (Belanger
et al., 1998).
Lack of UGT specificity
Current knowledge holds that each UGT has the ca-
pacity to glucuronidate a large range of substrates
(Table 1) and that one compound may be glucuron-
idated by several UGTs; however, some substrates
are solely or predominantly glucuronidated by a
single UGT (e.g. bilirubin and UGT1A1) (Mackenzie
et al., 2000).
The lack of specificity of UGT is well exemplified by
acetaminophen glucuronidation. UGT1A9 may be the
predominant UGT to glucuronidate this compound in
typical doses, while UGT1A6 may be more active at
low concentrations. UGT1A1 may also intervene with
toxic concentrations (Court et al., 2001).
In the liver, the active T4 and the inactive rT3 ap-
pear to be substrates of UGT1A1, while in extrahepatic
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tissues UGT1A9 may also intervene (Findlay et al.,
2000). Hyodeoxycholic acid is a substrate for UGT2B4
but it can be glucuronidated by other UGTs, particu-
larly UGT2B7.
There is substantial overlap between different UGTs
regarding the metabolism of sexual steroids. An in-
vitro study (Turgeon et al., 2001) demonstrated that
androstenodiol, testosterone, and dihydrotestosterone
were glucuronidated by UGT2B7, UGT2B15 and
UGT2B17. Androsterone, the main androgen metab-
olite, was glucuronidated by UGT2B7 and UGT2B17.
Oestrogens, including oestradiol, appear to be con-
jugated by UGT2B7 and UGT1A9 (Albert et al., 1999;
Turgeon et al., 2001). Catechol oestrogens (the most
potent naturally occurring inhibitors of catecholamine
metabolism) appear to be conjugated by UGT1A1,
UGT1A3 and UGT2B7 (Cheng et al., 1998; Turgeon
et al., 2001).
Psychopharmacological medications metabolized
by UGT enzymes
The pharmacokinetic and pharmacodynamic aspects
of the action of glucuronides of psychopharmacologi-
cal compounds has not been well studied in humans
(Hawe, 1998). The literature provides limited infor-
mation in this area (Table 3). It is generally thought
that glucuronidation is a way of detoxification of a
compound but this may not always be true. Some-
times glucuronides are not rapidly excreted and ac-
cumulation during long-term therapy occurs with a
variety of compounds. Some researchers have specu-
lated that glucuronides may represent an internal
storage system from which the active parent com-
pound may be recruited by deconjugation (Kroemer
and Klotz, 1992). There have been some reports of
pharmacological activity and toxicity of certain glu-
curonides (Clarke and Burchell, 1994; Kroemer and
Klotz, 1992). In an isolated study the administration
of a glucuronide, of the psychiatric medication ami-
tryptiline, demonstrated its activity by inducing the
rapid onset of side-effects (Breyer-Pfaff et al., 1990).
UGTmetabolizes some of the typical antipsychotics,
such as the phenothiazines, loxapine and haloperidol
(Shen, 1997). An earlier study suggested a link be-
tween the glucuronidation activity with side-effects
of phenothiazines (Wright et al., 1983). According
to Green and Tephly (1998) chlorpromazine, tri-
fluoperazine, and loxapine are substrates of UGT1A4.
The possibility that glucuronidation may be an im-
portant metabolic pathway for haloperidol has re-
cently been receiving attention. In a review, Kudo
and Ishizaki (1999) described that glucuronidation
of haloperidol accounts for 50–60% of human
metabolism. Haloperidol metabolism is induced by
smoking (Perry et al., 1993; Shimoda et al., 1999).
Haloperidol does not appear to be metabolized by
CYP1A2 (an enzyme induced by smoking) (Mihara
et al., 2000). Pan and Belpaire (1999) suggested that
smoking may induce haloperidol metabolism by in-
ducing UGTs.
Glucuronidation may also be an important pathway
for clozapine (Luo et al., 1994). According to Green
and Tephly (1998), clozapine and desmethylclozapine
(the main clozapine metabolite) are substrates of
UGT1A4. Clozapine is also a substrate of UGT1A3. In
a more recent in-vitro study, Breyer-Pfaff and Wachs-
muth (2001) described that clozapine-5-N-glucuronide
and desmethylclozapine-5-N-glucuronide are found
in small percentages in the urine (<1% of clozapine
doses). However, these low concentrations may reflect
that as 5-N-glucuronide clozapine metabolites are
labile under acidic conditions, they can, therefore,
be deconjugated in the urine.
Olanzapine-10-N-glucuronide appears to make up
approx. 25% of the metabolic clearance of olanzapine
(Callaghan et al., 1999; Hagg et al., 2001; Kassahun
et al., 1998). Markowitz et al. (2002) suggested in a re-
cent clinical study using probenecid, a UGT inhibitor,
that olanzapine (but not risperidone) is a substrate of
UGT, possibly UGT1A4. An in-vitro study also sup-
ported the role of UGT1A4 (Linnet and Olesen, 2001).
Carbamazepine induces olanzapine metabolism lead-
ing to considerable decrease (30–50%) of plasma
olanzapine concentration (Licht et al., 2000; Lucas
et al., 1998; Olesen and Linnet, 1999). The inductive
effects of carbamazepine had been posited to be
mediated by CYP1A2 induction (Callaghan et al.,
1999; Lucas et al., 1998). More recently, Linnet and
Olsen (2002) have demonstrated that the induction
of glucuronidation may be more important than the
CYP1A2 induction. They measured plasma olanza-
pine and olanzapine-10-N-glucuronide concentrations
and found that, in patients co-medicated with car-
bamazepine, plasma olanzapine-10-N-glucuronide ac-
counted on average for 79% of plasma concentrations.
In patients taking olanzapine only, olanzapine-10-
N-glucuronide concentrations accounted on average
for only 43% of plasma concentrations. They also
suggested that the other glucuronide, olanzapine-4-
N-glucuronide, is found in very low concentrations
in plasma.
The potent inhibition of glucuronidation of sexual
steroids by tertiary amine drugs such as chlorproma-
zine, amitriptyline and imipramine may be an import-
ant issue (Sharp et al., 1992). Direct inhibition of UGTs
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could significantly alter the production of steroid glu-
curonides and may contribute to the sexual side-
effects of antipsychotics or TCAs (Sharp et al., 1992).
Imipramine, amitriptyline, chlorimipramine and
doxepin are substrates of UGT1A4 (Green et al., 1998;
Green and Tephly, 1998). A recent in-vitro imipramine
study using 14 human liver microsomes found inter-
individual glucuronidation activity differences at most
of 2.5-fold (Nakajima et al., 2002). A study of plasma
levels in 108 Japanese patients taking chlorimipramine
showed that there were 28-fold variations in glucuron-
idation and that benzodiazepine intake and female
gender appear to be associated with decrease in glu-
curonidation (Shimoda et al., 1995). The N-dimeth-
ylated metabolites, desimipramine, and nortriptyline,
are not substrates of UGT1A3 or UGT1A4 (Green et al.,
Table 3. Glucuronidation of psychiatric drugs and of substances liable to be abused
Substrates Glucuronides UGT Metabolism (%)
Antidepressants
Amitriptyline Amitryptiline-N-glucuronide UGT1A4/A3 25%a
Chlorimipramine 8-OH-chlorimipramine-glucuronide UGT1A4 –
8-OH-norchlorimipramine-glucuronide – –
Doxepin – UGT1A4 >20%b
Imipramine – UGT1A4 –
Nortriptyline E-10-hydroxynortriptyline-glucuronide – –
Trazadone – – <1%c
Antipsychotics
Chlorpromazine Chlorpromazine-N-glucuronide UGT1A4 –
Clozapine Clozapine-5-N-glucuronide UGT1A4/A3 1%d, 3%c for
Norclozapine-5-N-glucuronide UGT1A4 both metabolites*
Haloperidol Haloperidol-glucuronide – 50–60%e for
Reduced haloperidol-glucuronide – both metabolites
Loxapine – UGT1A4 2%c
Olanzapine Olanzapine-10-N-glucuronide UGT1A4 >25%f
Olanzapine-4-N-glucuronide >5%f
Trifluoperazine – UGT1A4 –
Benzodiazepines
Lorazepam Lorazepam-hydroxy-glucuronide UGT2B7? >80%g, 92%a
Oxazepam Oxazepam-hydroxy-glucuronide UGT2B7? 86%a
Mood stabilizers
Carbamazepine Carbamazepine-10,11-trans-diol-glucuronide – 15%h
Lamotrigine Lamotrigine 2-N-glucuronide UGT1A4 65%h, 86%i, 89%a,
Lamotrigine 5-N-glucuronide – for both metabolites
Valproic acid Valproate-glucuronide Several? 33%a, 40%h, f60%i
Several metabolite-glucuronides – –
Substances liable to be abused and related medications
Buprenorphine – UGT2B7/1A1 –
Codeine Codeine-6-O-glucuronide UGT2B7 45%a, 70%i
Morphine Morphine-6-glucuronide UGT2B7 55%a for
Morphine-3-glucuronide UGT2B7 both metabolites
Naloxone – UGT2B7 60%a, 60–70%i
Naltrexone – UGT2B7/1A1 –
Nicotine Nicotine-glucuronide – 4%j
Cotinine-glucuronide – 13%j
3k-hydroxycotinine-glucuronide – 7%j
* Low percentage may reflect deglucuronidation in urine. –, Indicates that information is not described in the literature.
?, Indicates uncertainty. aMiners and Mackenzie (1991); b Hawes (1998); c Luo et al. (1995); d Breyer-Pfaff and Wachsmuth
(2001); e Kudo and Ishizaki (1999); f Kassahun et al. (1998); g Samara et al. (1997); h Anderson (1998); i Bertz and Granneman
(1997); j Benowitz and Jacob (1997).
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1998; Green and Tephly, 1998) but some of the
nortriptyline metabolites appear to be eliminated by
glucuronidation (Liston et al., 2001). Trazadone also
appears to be metabolized by glucuronidation (Luo
et al., 1995). Two case reports have suggested that
some selective serotonin reuptake inhibitors may in-
hibit UGTs (Haffen et al., 1999; Kauffman and Gerner,
1998).
Most benzodiazepines are metabolized by CYPs
and then by UGTs. However, lorazepam and oxa-
zepam are only metabolized by glucuronidation. As
described previously, Patel et al. (1995b) suggested
that 10% of Caucasians are poor glucuronidators of
S-oxazepam but it is not clear whether UGT2B7metab-
olizes oxazepam. Lorazepam is not a substrate of
UG1A1, but appears to be a non-competitive inhibitor
that may have a negative influence in patients with
Gilbert’s syndrome who already have an impaired
glucuronidation of bilirubin (Burchell et al., 2000). In
another study, the co-administration of valproic acid
was associated with mild and not clinically significant
increases of lorazepam levels (Samara et al., 1997). A
recent case report of a coma after a combination of
lorazepam and valproic acid questions the possibility
that in some patients this combination may have
clinical significance (Lee et al., 2002).
There is an even greater relationship between
anti-epileptics/mood stabilizers and glucuronidation.
Phenytoin, primidone and phenobarbital can induce
glucuronidation (Hachad et al., 2002). Glucuronida-
tion is probably the most important metabolic path-
way for valproic acid accounting for 33–60% of its
metabolism (Table 3). It has been suggested that val-
proic acid may be a substrate for UGT2B7 (de Wildt
et al., 1999; Liston et al., 2001), UGT1A3 (Liston et al.,
2001) or UGT1A6 and UGT1A9 (Burchell et al., 2000).
The UGTs account for approx. 15% of carbama-
zepine metabolism (Anderson, 1998). Oxcarbazepine
is also metabolized by glucuronidation (Baruzzi et al.,
1994). Valproic acid inhibits carbamazepine metab-
olism. Bernus et al. (1997) found, in 17 patients, that
this inhibition is partly explained by an inhibition of
the glucuronidation of a carbamazepine metabolite.
Carbamazepine, an inducer of some metabolic en-
zymes including glucuronidation enzymes, increases
the glucuronidation of valproic acid.
Lamotrigine is a weak inducer of glucuronidation
and of its own metabolism. Glucuronidation is the
major metabolic pathway, accounting for up to 65–
90% of lamotrigine metabolism (Table 3). The main
urine metabolite is the inactive 2-N-glucuronide
(Hachad et al., 2002). Recent reviews (Burchell et al.,
2000; Liston et al., 2001) suggest that UGT1A4 may
metabolize lamotrigine. Co-administration with val-
proic acid decreases lamotrigine metabolism and may
increase the risk of a skin rash associated with lamo-
trigine. In clinical settings, it is important to decrease
the initial dose of lamotrigine in patients taking val-
proic acid (Page et al., 1998). It has also been suggested
that sertraline increased lamotrigine levels and tox-
icity by inhibiting glucuronidation (Kauffman and
Gerner, 1998). UGT inducers such as phenytoin, carb-
amazepine, and phenobarbital increase lamotrigine
metabolism. Hachad et al. (2002) suggested that
the inhibitory effect of valproic acid in lamotrigine
metabolism is stronger than inductive effects of carb-
amazepine and phenobarbital. However, when val-
proic acid is combined with phenytoin, the effects of
both drugs on lamotrigine metabolism compensate for
each other.
UGTs and substance abuse
Recently it has been found that a lack of certain meta-
bolic enzymes may influence substance addiction.
CYP2D6 activates codeine and transforms it into
morphine; poor CYP2D6 metabolizers, lacking
CYP2D6, may be protected from codeine abuse (Tyn-
dale et al., 1997). Similar associations with CYP2A6
have been reported for nicotine. Nicotine is primarily
metabolized to its main metabolite, cotinine, by
CYP2A6. Cotinine is further metabolized by CYP2A6
to trans-3k-hydroxycotinine. It appears that East Asians
who are deficient in CYP2A6 smoke less cigarettes
(Raunio et al., 2001; Tyndale and Sellers, 2002).
Glucuronidation may also influence opioid and
nicotine addiction. Racial differences in glucuronida-
tion may influence codeine use (Kroemer and Klotz,
1992). Morphine is glucuronidated in a stereoselective
manner to morphine-3-glucuronide and morphine-
6-glucuronide. The administration of morphine-6-glu-
curonide by the intrathecal or intracerebroventricular
routes reveals that this compound is 45–800 times
more potent than the parent drug (Christup, 1997).
Given systemically, it appears to be twice as potent
as morphine in animal models and human beings.
Morphine-3-glucuronide appears to be an antagonist of
morphine and has been suggested to contribute to side-
effects such as the hyperalgesia and myoclonus dur-
ing high-dose morphine treatment in rats (Christup,
1997). It is surprising that morphine glucuronides
have any CNS activity at all. As a rule, glucuronides
are considered highly polar compounds unable to
cross the blood–brain barrier. However, it is clear that
morphine glucuronides, in spite of the high polarity,
do cross the blood–brain barrier, but the mechanism
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and extent are unclear. It has been suggested that
morphine glucuronides may mediate morphine in-
toxication in some pathological conditions such as
renal failure. In renal failure, the glucuronides will
not be eliminated in urine, so they are available for
deconjugation (Kroemer and Klotz, 1992).
Morphine, codeine, naloxone, naltrexone, and bu-
prenorphine appear to be substrates of UGT2B7 (de
Wildt et al., 1999; Liston et al., 2001). Naltrexone and
buprenorphine also appear to be UGT1A1 substrates
(King et al., 1996). During an in-vitro study, Whal-
strom et al. (1994) found that concentrations of TCAs,
close to those achieved in patients’ plasma, inhibited
morphine glucuronidation. This may potentiate an-
algesia but can also produce adverse side-effects.
Up to 25% of nicotine metabolism can be explained
by glucuronidation (Benowitz and Jacob, 1997). Nic-
otine suffers glucuronidation (Byerly et al., 2000) and
the same happens for the main metabolites cotinine
and 3k-hydroxycotinine (Figure 1). Racial differences
in nicotine clearance may be affected by UGT activity.
African–Americans do not eliminate nicotine as well
as Caucasians (Perez-Stable et al., 1997; Caraballo
et al., 1998). Benowitz et al. (1999) measured urine
concentration of nicotine metabolites including the
glucuronides of nicotine, cotinine, and 3k-hydroxy-
cotinine. They described slow metabolizers for nic-
otine and cotinine glucuronidation as overrepresented
among African–Americans in their sample. They also
indicated that the same enzyme probably performed
the N-1-glucuronidation of nicotine and cotinine, but
the O-glucuronidation of 3k-hydroxycotinine is prob-
ably conducted by another UGT.
The problem with measuring nicotine metabolite-
glucuronides is that nicotine-glucuronide (Byrd et al.,
2000) and cotinine-glucuronide have been synthesized
(Caldwell et al., 1992) and can be used as analytical
standard. However, 3k-hydroxycotinine-glucuronide
has not been synthesized and cannot be used as stan-
dard in analytical methods (Ghosheh et al., 2000). The
first study measuring plasma cotinine glucuronide
and 3k-hydroxycotinine-glucuronide (de Leon et al.,
2002) suggested, as did the urine study by Benowitz
et al. (1999), that the glucuronidation of cotinine and
3k-hydroxycotinine is conducted by two different
UGTs. Moreover, the low stability of plasma cotinine
glucuronide suggests it may undergo in-vivo decon-
jugation by b-glucuronidase (de Leon et al., 2002).
A second study of plasma nicotine metabolites com-
pared American Caucasians and African–American
smokers (de Leon et al., In Press). Although it was
too small, it was compatible with the findings of
Benowitz et al. (1999) that African–Americans may be
overrepresented among the slow metabolizers for the
glucuronidation of cotinine.
Benowitz and Jacob (2000) found that cigarette
smoking markedly induced O-glucuronidation of
3k-hydroxycotinine but did not influence N-1-glucu-
ronidation of nicotine and cotinine. Recently, in an
in-vitro study, Ghosheh and Hawes (2002) found that
cotinine or nicotine were not substrates of ten UGTs
tested.
UGTs in the brain
The UGT1A family probably conjugates serotonin
since some patients with Crigler–Najjar syndrome are
poor glucuronidaters of this compound (Burchell and
Coughtrie, 1997). King et al. (1999) suggested that
serotonin may be a substrate of brain UGT1A6 (and of
UGT2B7 that is less efficient).
The presence of large quantities of dopamine glu-
curonide in rat CSF suggests the involvement of UGTs
in the metabolism of dopamine of central origin
(Wang et al., 1983). However, it would be important
to know how active this pathway is in humans (Wang
et al., 1983).
Animal studies have identified small concentrations
of UGTs in brain tissue. However, UGTs and other
metabolic enzymes appear to be in higher concen-
trations at brain capillaries and they appear to be as-
sociatedwith theblood–brainbarrier (Minnet al., 1991).
A few human brain studies have shown a limited
concentration of UGTs in brain tissue. However, these
human studies have a major limitation in that they
tend to use UGT substrates extrapolated from animal
models to identify UGTs in brain tissue. The identifi-
cation of human UGT genes will help determine
whether or not they are expressed in the human brain,
and their location.
Very small concentrations of metabolic enzymes,
CYPs or UGTs, may have a major effect if they are
located to protect a specific set of neurons from a toxin.
The small concentration in some brain areas may be
not important in the global metabolism when com-
pared to the liver metabolic enzymes. However, if a
dietary compound has specific neurotoxicity by inter-
fering with a specific neurotransmitter receptor, the
metabolic enzyme located in that area of the brain may
be important in order to detoxify any remaining toxin
escaping detoxification by the liver or other organs
(Britto and Wedlund, 1992).
In summary, this review tries to illustrate the im-
portance of glucuronidation and the implications for
psychiatry. Hopefully, when a psychiatrist or a psy-
chiatric researcher sees the word ‘glucuronidation’ or
Glucuronidation enzymes, genes and psychiatry 67
‘UGT’ in an article or other publication, they will not
dismiss the subject lightly. In the next 10 years, ad-
vances in genetic mapping are going to provide new,
revolutionary, and shocking findings in our under-
standing of the genetics of severe mental illnesses
and glucuronidation genes may prove important to
understanding or treating these conditions. For the
sceptics who feel that glucuronidation genes may have
little significance in the field of psychiatry, imagine
what he/she would have thought several years ago if
someone tried to convince him/her that a protein re-
lated to cholesterol metabolism (ApoE) was related to
Alzheimer’s disease. In the future, the impact of UGT
genetic variability should be evaluated in concert with
polymorphic variations of CYP and other phase I
enzymes.
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